Why Is Solu-Cortef So Hard to Find? [Explained for 2026]

If you or a loved one relies on Solu-Cortef (hydrocortisone sodium succinate injection) and have run into trouble finding it at your local pharmacy or hospital supplier, you are not alone. This critical injectable corticosteroid has experienced repeated supply disruptions — most notably in 2023 and again in 2025 — leaving patients with adrenal insufficiency, Addison's disease, and other serious conditions scrambling for alternatives.

In this article, we break down exactly why Solu-Cortef is hard to find, what drove past shortages, and what the supply situation looks like heading into 2026 — so you can plan ahead and protect your health.

What Is Solu-Cortef and Why Is It So Important?

Solu-Cortef is the brand name for hydrocortisone sodium succinate, an injectable form of hydrocortisone made by Pfizer. It is a fast-acting corticosteroid given by intravenous (IV) or intramuscular (IM) injection when patients cannot take oral steroids or need rapid treatment. Effects are evident within one hour of IV administration.

For patients with adrenal insufficiency or Addison's disease, Solu-Cortef is not just a convenience — it can be a life-saving emergency medication. These patients are often prescribed the ACT-O-VIAL home kit to self-inject during an adrenal crisis. When supply is disrupted, the consequences can be severe.

Beyond adrenal conditions, Solu-Cortef is used in hospitals every day for severe allergic reactions, autoimmune flares, septic shock, status asthmaticus, and many other acute conditions. Hospitals stock it routinely, which means when supply tightens, the ripple effects are felt by many patients simultaneously.

The 2023 Solu-Cortef Shortage: What Happened?

In March 2023, Pfizer announced a supply disruption affecting the Solu-Cortef 100 mg/2 mL ACT-O-VIAL Single Dose Vial presentation. The disruption was attributed to quality control issues and increased demand. Pfizer restricted distribution to direct orders only, allocating limited quantities to institutions with a documented history of purchases.

To help manage the crisis, the FDA granted an emergency expiration date extension — extending 32 lots of Solu-Cortef by five months beyond their labeled 36-month expiry date. The original estimated recovery date was June 2023, but the situation extended into late 2023. Pfizer opened a Supply Continuity Team hotline (1-844-646-4398) to help facilities obtain emergency access to available product.

Research has shown that approximately 64% of drug shortages are caused by quality problems — and the 2023 Solu-Cortef disruption fit that pattern. Quality issues at a single manufacturer can rapidly cascade into a nationwide shortage when that manufacturer is the dominant (or sole) supplier.

The April 2025 Supply Interruption

In April 2025, Pfizer notified healthcare customers of another short-term interruption, this time affecting the 25-pack presentation of the Solu-Cortef 100 mg/2 mL ACT-O-VIAL. The cause was cited as increased demand combined with a manufacturing delay — which Pfizer stated had since been resolved. The FDA was again notified, and Pfizer projected restoration to normal supply levels by Q3 2025.

As of October 2025, the American Society of Health-System Pharmacists (ASHP) updated its drug shortage database to note that "Pfizer has all Solu-Cortef presentations available" — a positive sign that supply had normalized. However, given the repeated disruptions, patients and providers should remain vigilant and not assume availability will be consistent at every pharmacy or distributor.

Why Is Solu-Cortef Especially Vulnerable to Shortages?

Several structural factors make Solu-Cortef more prone to shortages than many other drugs:

Single dominant manufacturer: Pfizer is the primary manufacturer of branded Solu-Cortef in the U.S. While generics exist (A-Hydrocort), they are not as widely stocked in all settings.

Complex manufacturing process: Injectable sterile powders require strict manufacturing conditions. Quality deviations — even minor ones — can force batch recalls and production halts.

Surge demand scenarios: Pandemics, influenza seasons, and other public health crises create sudden spikes in demand for corticosteroids like hydrocortisone, rapidly depleting safety stock.

Hospital-centric distribution: Most Solu-Cortef is distributed through hospital/wholesaler channels, not retail pharmacies. Retail pharmacy patients may find it harder to source, especially the 100mg ACT-O-VIAL home emergency kits for adrenal crisis.

Preservative-free formulation requirements: The ACT-O-VIAL system is preservative-free, which adds complexity to both manufacturing and shelf-life management.

Is Solu-Cortef in Shortage in 2026?

As of early 2026, Solu-Cortef is not listed as an active FDA drug shortage. Supply appears to have stabilized following the 2025 interruption. However, "not in shortage" nationally does not mean every pharmacy or distributor has it in stock right now.

Localized availability gaps remain common with injectable hospital drugs. A hospital pharmacy in one city may have ample supply while a retail pharmacy or smaller clinic in another area runs dry. This is one of the key reasons patients and providers need a reliable way to check real-time pharmacy inventory.

What Can Patients Do When Solu-Cortef Is Hard to Find?

If you are having trouble filling a Solu-Cortef prescription — especially for a home emergency kit — here are the steps experts recommend:

Contact your endocrinologist or prescriber immediately. They may be able to route the prescription through a hospital pharmacy or compounding pharmacy that has stock.

Ask about the generic alternative. A-Hydrocort is the generic version of Solu-Cortef. If the brand is unavailable, the generic may be in stock at a different pharmacy.

Call multiple pharmacies. Availability varies widely by location. Calling 5-10 pharmacies manually can be time-consuming but effective.

Use medfinder. medfinder calls pharmacies near you on your behalf to check which ones can fill your Solu-Cortef prescription, saving you hours of phone calls.

Discuss alternatives with your doctor. If Solu-Cortef is truly unavailable, alternatives like dexamethasone sodium phosphate or methylprednisolone sodium succinate (Solu-Medrol) may serve as temporary substitutes in some clinical situations — though they lack mineralocorticoid activity and may require fludrocortisone supplementation for adrenal insufficiency patients.

The Bottom Line on Solu-Cortef Availability in 2026

Solu-Cortef's shortage history reflects a broader fragility in the U.S. sterile injectable drug supply chain. While the current situation has improved, patients — especially those with adrenal insufficiency who depend on home emergency kits — should proactively check inventory and keep their care team informed. Tools like medfinder can help you quickly identify which pharmacies near you have Solu-Cortef in stock, so you are never caught without this essential medication.

Want a deeper look at the current shortage status? Read our Solu-Cortef shortage update for 2026 for the latest details. If you're weighing alternatives, see our guide to Solu-Cortef alternatives if you can't fill your prescription.